CMA fines pharma firm over pricing of crucial thyroid drug
The CMA has imposed over £100 million in fines after Advanz inflated the price of thyroid tablets, causing the NHS and patients to lose out.
From:
29 July 2021
Advanz increased the price of thyroid tablet packs from £20 in 2009 to £248 in 2017 – an increase of 1,110%.
Latest CMA fine “sends a clear message” to the pharma sector that breaking the law will not be tolerated.
Following an investigation, the Competition and Markets Authority (CMA) has found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency.
Investegate |Competition and Mkts Announcements | Competition and Mkts: CMA finds drug companies overcharged NHS
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Mattioli Woods PLC Announcements | Mattioli Woods PLC: Director Appointment
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Press Release – Te Putahitanga o Te Waipounamu Te Ptahitanga o Te Waipounamu has released its annual report for the year ended 30 June 2020, following this weeks meeting of its General Partner Limited (GPL) board. Chair T Mark Solomon says that the board is proud to present this years …
Te Pūtahitanga o Te Waipounamu has released its annual report for the year ended 30 June 2020, following this week’s meeting of its General Partner Limited (GPL) board.
Chair Tā Mark Solomon says that the board is proud to present this year’s results, which reflect the amazing effort that the Whānau Ora commissioning agency has made in response to the challenges of COVID-19.